Since Brett Veach took over as general manager in 2018, the Chiefs have traded up four times for their initial section of any ...

One month will define the Colorado Buffaloes' future. January brings a bevy of roster-building opportunities for coach Deion ...

NFL player and New England Patriots wide receiver Stefon Diggs, who recently welcomed a child with singer Cardi B, is facing ...

It's Christmas Day and the Denver Broncos are playing football! The Broncos (12-3) will take on the Kansas City Chiefs (6-9) at Arrowhead Stadium and though the Chiefs have had an incredibly ...

With a fresh FDA endorsement for its drug plozasiran, California-based Arrowhead Pharmaceuticals has successfully broken through to the commercial realm. Complicating the matter, however, is the fact ...

The Kansas City Chiefs have been one of the NFL’s most dominant teams of the last decade, winning three Super Bowl championships and playing in seven straight AFC Championship games. And while the ...

Close-up of Hyptiotes cavatus spider holding triangle web support line with front legs keeping web open, while using back legs to secure anchor line. When back legs release anchor line, spider and web ...

The Chiefs continue to move toward an inevitable decision between renovating Arrowhead Stadium and building a new stadium. On Monday, Chiefs owner Clark Hunt addressed the status of the team’s effort ...

Pasadena-based Arrowhead Pharmaceuticals Inc. has announced another major licensing deal with a pharma giant. This one is with Basel, Switzerland-based Novartis for $200 million in upfront payment and ...

Sept 11 (Reuters) - Ionis Pharmaceuticals (IONS.O), opens new tab sued biotech rival Arrowhead Pharmaceuticals (ARWR.O), opens new tab for patent infringement in California federal court on Thursday ...

Arrowhead Pharmaceuticals has launched legal action against Ionis Pharmaceuticals, aiming to neutralize Ionis' claim that Arrowhead's potential rival to Tryngolza breaches a patent. Arrowhead claims ...

Novartis has been on a deal-making spree in 2025, including buyouts and licensing pacts, as it prepares for looming patent expirations on several blockbuster medicines. H.C. Wainwright analysts said ...